Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

M6620 e carboplatino con o senza docetaxel nel trattamento di pazienti con carcinoma prostatico metastatico resistente alla castrazione

11 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Uno studio di fase 2 su M6620 (VX-970, Berzosertib) in combinazione con carboplatino rispetto a docetaxel in combinazione con carboplatino nel carcinoma prostatico metastatico resistente alla castrazione

This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer compared to carboplatin and docetaxel alone.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVE:

I. To assess the difference in response rate (either achievement of prostate specific antigen [PSA] reduction of greater than 50% or radiographic response by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) of the combination of berzosertib (M6620) (VX-970, berzosertib) and carboplatin as compared to the combination of docetaxel and carboplatin.

SECONDARY OBJECTIVES:

I. To assess the difference in time to PSA progression by Prostate Cancer Working Group (PCWG)2 criteria of the combination of M6620 (VX-970, berzosertib) and carboplatin as compared to the combination of docetaxel and carboplatin.

II. To describe radiographic progression-free survival and progression-free survival by PCWG3 criteria in both arms of the study.

III. Assess the relationship with homologous recombination deficiency (HRD) detected from baseline tumor biopsy with response to the combination of M6620 (VX-970, berzosertib) and carboplatin and the combination of docetaxel and carboplatin.

IV. To describe the safety and adverse events from the combination of M6620 (VX-970, berzosertib) + carboplatin as well the combination of docetaxel + carboplatin.

EXPLORATORY OBJECTIVES:

I. Comparison of overall survival in the two arms of the study. II. Explore response rate, time to PSA progression, radiographic progression-free survival, and progression-free survival by PCWG3 criteria in patients who initially receive docetaxel + carboplatin after crossover to M6620 + carboplatin.

III. To assess the relationship with homologous recombination deficiency (HRD) detected from baseline circulating free deoxyribonucleic acid (DNA) (cfDNA) with response to the combination of M6620 and carboplatin and the combination of docetaxel and carboplatin, and describe alterations seen in cfDNA (and optional tumor biopsy) at end of study.

OUTLINE: Patients are randomized to 1 of 2 groups.

ARM A (docetaxel, carboplatin): Patients receive docetaxel intravenously (IV) over 60 minutes and carboplatin IV over 30 minutes on day 1 or carboplatin alone on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients have PSA progression or radiographic progression may crossover to Arm B.

ARM B (carboplatin, berzosertib): Patients receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up between 30-42 days.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

73

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Duarte, California, Stati Uniti, 91010
        • City of Hope Comprehensive Cancer Center
      • La Jolla, California, Stati Uniti, 92093
        • UC San Diego Moores Cancer Center
      • Sacramento, California, Stati Uniti, 95817
        • University of California Davis Comprehensive Cancer Center
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • UCHealth University of Colorado Hospital
    • Connecticut
      • Derby, Connecticut, Stati Uniti, 06418
        • Smilow Cancer Hospital-Derby Care Center
      • Fairfield, Connecticut, Stati Uniti, 06824
        • Smilow Cancer Hospital Care Center-Fairfield
      • Guilford, Connecticut, Stati Uniti, 06437
        • Smilow Cancer Hospital Care Center - Guilford
      • Hartford, Connecticut, Stati Uniti, 06105
        • Smilow Cancer Hospital Care Center at Saint Francis
      • New Haven, Connecticut, Stati Uniti, 06520
        • Yale University
      • New Haven, Connecticut, Stati Uniti, 06510
        • Smilow Cancer Center/Yale-New Haven Hospital
      • North Haven, Connecticut, Stati Uniti, 06473
        • Yale-New Haven Hospital North Haven Medical Center
      • Orange, Connecticut, Stati Uniti, 06477
        • Smilow Cancer Hospital-Orange Care Center
      • Torrington, Connecticut, Stati Uniti, 06790
        • Smilow Cancer Hospital-Torrington Care Center
      • Trumbull, Connecticut, Stati Uniti, 06611
        • Smilow Cancer Hospital Care Center-Trumbull
      • Waterbury, Connecticut, Stati Uniti, 06708
        • Smilow Cancer Hospital-Waterbury Care Center
      • Waterford, Connecticut, Stati Uniti, 06385
        • Smilow Cancer Hospital Care Center - Waterford
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Stati Uniti, 02215
        • Dana-Farber Cancer Institute
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48201
        • Wayne State University/Karmanos Cancer Institute
    • New Jersey
      • New Brunswick, New Jersey, Stati Uniti, 08903
        • Rutgers Cancer Institute of New Jersey
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43210
        • Ohio State University Comprehensive Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232
        • UPMC Hillman Cancer Center
    • Virginia
      • Richmond, Virginia, Stati Uniti, 23298
        • VCU Massey Comprehensive Cancer Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion Criteria:

  • Participants must have histologically or cytologically confirmed prostate cancer (code 10036910) with progressive disease at the time of study entry by either

    • Sequence of at least 2 rising PSA values at a minimum of 1-week intervals
    • Radiographic progression per RECIST1.1 for soft tissue and/or per PCWG3^2 for bone, with or without PSA progression
  • Patients must have metastatic disease by bone scan or other nodal or visceral lesions on computed tomography (CT) or magnetic resonance imaging (MRI) and a castrate level of testosterone (< 50 ng/dL) and evaluable for disease response by either

    • Baseline PSA >= 2.0 ng/mL OR
    • Measurable disease per RECIST 1.1
    • NOTE: Subjects must maintain a castrate state; if they have not had an orchiectomy, they must continue to receive luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists or antagonists unless intolerant
  • At least 2 prior treatments for castration resistant prostate cancer as follows:

    • Past progression or intolerance to at least one secondary hormonal therapy (abiraterone, enzalutamide, galeterone, apalutamide, darolutamide, orteronel, seviteronel or equivalent)
    • Past progression or intolerance to taxane-based chemotherapy
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

  • Leukocytes >= 3,000/mcL

  • Absolute neutrophil count >= 1,500/mcL

  • Hemoglobin >= 9 g/dL (transfusion permitted)

  • Platelets >= 150,000/mcL (without transfusion or growth factor in prior 28 days)

  • Total bilirubin =< 1.5 x institutional upper limit of normal, unless the subject has known or suspected Gilbert's syndrome

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal or =< 5 x if presence of liver metastases

  • Creatinine clearance >= 40 mL/min/1.73 m^2

  • Prior treatment with mTOR inhibitors, cytostatic tyrosine kinase inhibitor (TKI), or biologic therapies allowed

  • Prior treatment with PARP inhibitors permitted

  • Patients with allergy or intolerance to docetaxel, grade 2 neuropathy are allowed on study, but if randomized to Arm A will receive carboplatin as a single agent (area under curve [AUC] 5) rather than docetaxel+carboplatin; they must be fit for carboplatin chemotherapy as determined by the treating investigator

  • Presence of a lesion (bone or soft tissue) amenable to image-guided percutaneous biopsy adequate for next generation sequencing (NGS), and planned to undergo core biopsy after trial registration but prior to cycle 1 day 1 of therapy; confirmation of adequacy of this biopsy material for NGS is NOT required for initiation of therapy; if elective biopsies are not being performed at the treating institution due to preparations or precautions related to coronavirus disease 2019 (COVID-19), this requirement can be waived on discussion with the trial principal investigator (PI)

  • The effects of M6620 (VX-970, berzosertib), carboplatin and docetaxel on the developing human fetus are unknown. For this reason and because DNA-damage response inhibitors and chemotherapeutic agents are known to be teratogenic, men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of carboplatin and M6620 (VX-970, berzosertib) administration

  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to planned cycle 1 day 1 of study treatment; patients on an oral anti-neoplastic such as an oral hormonal agent, PARP inhibitor or oral experimental agent should discontinue >= 14 days prior to planned cycle 1 day 1 of study treatment

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), except for grade 2 anorexia, alopecia, neuropathy, and fatigue, for which resolution is not required

  • Patients who are receiving any other investigational agents

  • Patients with known brain metastases or leptomeningeal disease should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970, berzosertib) or carboplatin; (patients with allergy to docetaxel will be allowed on study, but docetaxel will be excluded from their treatment regimen)

  • Subjects receiving treatment with ototoxic or nephrotoxic medications that cannot be discontinued at least 7 days before first dose of carboplatin and for the duration of the study; inadvertent or short-term use on study will not cause a subject to be ineligible; if a short course of therapy with nephrotoxic or ototoxic medication is anticipated and required, carboplatin should be discontinued until 7 days after this course is completed; patients on continuous medications that are potentially nephrotoxic who have had no evidence of nephrotoxicity from these medications at study entry are allowed to continue those medicines on trial

    • M6620 (VX-970, berzosertib) is primarily metabolized by CYP3A4; therefore, concomitant administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir) or inducers of CYP3A4 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) is prohibited; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of; Patient Drug Information Handout and Wallet Card should be provided to patients; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Pregnant and nursing women are excluded from this study because they do not develop prostate cancer

  • Human immunodeficiency (HIV)-positive participants with detectable viral load and/or CD4 count =< 300 are ineligible due to increased risk of lethal infections when treated with marrow-suppressive therapy; HIV-positive patients with undetectable viral loads and CD4 counts > 300, and not on interacting antiretroviral therapy may be eligible after discussing with the principal investigator

  • Prior treatment with platinum-containing regimen or ATR inhibitor for prostate cancer

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Arm A (docetaxel, carboplatin)

Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes, or carboplatin alone on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who have PSA progression or radiographic progression may crossover to Arm B.

Given IV

Altri nomi:
  • Blastocarb
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platino
  • Ribocarbonio
  • JM8

Correlative studies

Given IV

Altri nomi:
  • Taxotere
  • Doccad
  • RP56976
  • Taxotere concentrato per iniezione
  • RP 56976
  • RP-56976
Sperimentale: Arm B (carboplatin, berzosertib)

Patients receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Given IV

Altri nomi:
  • Blastocarb
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platino
  • Ribocarbonio
  • JM8

Correlative studies

Given IV

Altri nomi:
  • 2-pirazinammina, 3-(3-(4-((Metilammino)metil)fenil)-5-isossazolil)-5-(4-((1-metiletil)solfonil)fenil)-
  • M6620
  • VX 970
  • VX-970
  • VX970

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Response Rate
Lasso di tempo: Radiologic measurements are performed every 3 cycles Up to 2 years. PSA measurements are performed every cycle up to 2 years

Defined by radiographic response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or prostate specific antigen [PSA] response (> 50% decline from baseline).

Radiologic measurements are performed every 3 cycles Up to 2 years. PSA measurements are performed every cycle up to 2 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free Survival (PFS)
Lasso di tempo: From the time of randomization up to 2 years

Assessed by Prostate Cancer Working Group (PCWG) 3 criteria. PFS to be estimated with the Kaplan Meier methodology. Median will be provided with 95% confidence interval.

From the time of randomization up to 2 years
Time to PSA Progression
Lasso di tempo: From the time of randomization up to 2 years

Assessed by PCWG2. PSA progression will be estimated with the Kaplan Meier methodology. Median will be provided with 95% confidence interval.

From the time of randomization up to 2 years
Radiographic Progression-free Survival (rPFS)
Lasso di tempo: From the time of randomization up to 2 years

Assessed by RECIST 1.1 for non-osseous disease and by PCWG3 for osseous disease. rPFS will be estimated with the Kaplan Meier methodology. Median will be provided with 95% confidence interval.

From the time of randomization up to 2 years
Incidence of Adverse Events
Lasso di tempo: Up to 2 years (from treatment initiation to 30 days after the last dose of study treatment)

Adverse events will be graded and analyzed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Up to 2 years (from treatment initiation to 30 days after the last dose of study treatment)

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Survival (OS)
Lasso di tempo: From the time of randomization up to 2 years

OS will be estimated with the Kaplan Meier methodology.

From the time of randomization up to 2 years
Gene Mutation Frequencies
Lasso di tempo: At baseline

The frequency of homologous recombination (HR) deficiency detected from baseline tumor biopsy is summarized by arm at baseline.

At baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Atish D Choudhury, Dana-Farber - Harvard Cancer Center LAO

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

29 maggio 2019

Completamento primario (Effettivo)

10 agosto 2021

Completamento dello studio (Stimato)

3 aprile 2027

Date di iscrizione allo studio

Primo inviato

7 maggio 2018

Primo inviato che soddisfa i criteri di controllo qualità

7 maggio 2018

Primo Inserito (Effettivo)

8 maggio 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NCI-2018-00790
  • UM1CA186709 (Sovvenzione/contratto NIH degli Stati Uniti)
  • NCI-2018-00790 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • 10191 (Altro identificatore: CTEP)
  • 10191 (Altro identificatore: Dana-Farber - Harvard Cancer Center LAO)

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi